目的选择能够早期反映同种异体原位肝移植术后他克莫司(FK506)对患者肾功能损伤的灵敏指标。方法回顾性分析我院自2000年2月至2005年5月的15例肾功能正常的肝移植患者的临床资料，重点分析其尿α1微球蛋白（α1MG）和微量白蛋白（mAlb）以及血肌肝（Cr）和尿素氮(BUN)与FK506血药浓度之间的关系。结果15例肝脏移植患者，尿α1MG及mAlb含量与FK506血药浓度呈正相关（r=0.939,P＜0.005; r=0.893, P＜0.05）， 血Cr及BUN与FK506血药浓度无相关性(r=0.490,Pgt;0.05； r=0.382,Pgt;0.05)。结论尿α1MG和mAlb可作为反映肾功能损伤的早期的灵敏指标，有利于监测肝移植术后FK506的理想全血浓度，能够为临床早期诊断和治疗肾功能损伤提供参考指标。
Objective To study the effects of pcDNA3/AFP/TK/Angio fusion gene targeting therapy for human primary liver cancer in nude mice implanted with SMMC-7721. Methods Human liver cancer cell line SMMC-7721 was implanted subcutaneously in nude mice to establish experiment model. Animals bearing liver cancer were randomly divided into five groups: control group， vector group， GCV (ganciclovir) group， pcDNA3/TK/Angio group; pcDNA3/AFP/TK/Angio group. Different plasmids were directly injected into tumors and GCV was intraperitoneally administrated simultaneously according to different groups. The growth of tumors was observed and the pathology was examined as well. Serum AFP level was measured by radioimmunology, the ultrastructural change of tumor cells was studied by using electron microscopy, the expressions of MVD and VEGF were respectively detected with immunohistochemistry and the cell apoptosis in situ was detected by TUNEL. Results The success rate to establish subcutaneous implanted liver cancer model in nude mice was 100%. The tumor volume, serum AFP level, VEGF and MVD expressions of pcDNA3/TK/Angio group and pcDNA3/AFP/TK/Angio group were lower than those in control group, vector group and GCV group (P＜0.05) and more apoptosis cells could be observed. While the tumor volume, serum AFP level, VEGF and MVD expressions of pcDNA3/AFP/TK/Angio group was lower than those in pcDNA3/TK/Angio group (P＜0.05); and apoptosis index was higher than that of the latter (P＜0.05).Conclusion pcDNA3/AFP/TK/Angio fusion gene inhibits the growth of tumor remarkably and becomes a promising new biological agent to treat human primary liver cancer.